Basic Information
Giapreza
Regulatory Information
EMEA/H/C/004930
Authorised
August 23, 2019
June 27, 2019
6
September 25, 2024
Company Information
Germany
Heussstrasse 25 Brand 52078 Aachen
Paion Pharma GmbH
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
Overview Summary
Giapreza is a medicine used in adults with dangerously low blood pressure (a condition known as shock). It is used when other treatments for raising blood pressure have not worked and contains the active substance angiotensin II.